Farmas USA

Sí, espero que a la larga merezca la pena aún haciendo las cagadas típicas de novato. De los errores se aprende, en cualquier caso gracias por los ánimos y por todo lo que estoy aprendiendo en este foro...

JUNO
Aqui tienes fuentes más fiables y más recientes:
CAR-T names higher after expert sees 'extraordinary' early success
Shares of several companies developing cell-based cancer immunotherapies are rising this morning after early trials of the potential cancer treatments were highlighted by an expert in the space at a medical conference for their "extraordinary" success. WHAT'S NEW: Professor Stanley Riddell from the Fred Hutchinson Cancer Research Center in Seattle discussed new adoptive T-cell strategies for cancer at the annual meeting of the American Association for the Advancement of Science, which ran over this past weekend. As part of a symposium on the promise and progress of T-cell therapy to fight human diseases, Riddell focused on an experimental immunotherapy, which uses T cells engineered with chimeric antigen receptors, or CARs, that is also known as CAR-T therapy. According to a recap of his presentation by Fox News, Hutchinson highlighted a study in which 94% of participants suffering from acute lymphoblastic leukemia saw their symptoms vanish completely after they were treated with modified T-cells. In another study, more than 50% of patients with non-Hodgkin's lymphoma ended up symptom-free, according to Fox News, which quoted Riddell as saying: "This is unprecedented in medicine to be honest, to get response rates in this range in these very advanced patients." WHAT'S NOTABLE: Cellectis (CLLS) is a genome editing firm specializing in immuno-oncology therapies. Cellectis aims to position its "universal" CART product line as an off-the-shelf treatment capable of meeting the demands of large patient populations. Other companies developing cell-based cancer immunotherapies include Juno Therapeutics (JUNO), bluebird bio (BLUE) and Kite Pharma (KITE). PRICE ACTION: In morning trading, Cellectis jumped 14.5%, Juno gained 6.6%, bluebird added 5.6% and Kite rose 1.5%.

La verdad es que los osos se lo curran ...

Vaya.

Venga, que hoy toca cerrar por encima de 5. Que nos devuelvan parte de lo que nos quitaron y rapidito.

NVAX

Creo que no lo ha subido nadie. Multita para GSK

http://www.pmfarma.es/noticias/22298-reino-unido-multa-a-la-farmaceutica-gsk-con-mas-de-48-millones.html

GSK

La farmacéutica Mylan adquiere la sueca Meda por 8.740 millones

http://www.pmfarma.es/noticias/22287-la-farmaceutica-mylan-adquiere-la-sueca-meda-por-8.740-millones.html

Mylan

http://thefly.com/landingPageNews.php?id=2328805&headline=NVAX-Novavax-analyst-commentary-

Novavax should be bought on weakness, says Wedbush
Wedbush says that the data for Novax's RSV drug, expected to be announced in Q3, should be positive. The firm says the company is well-capitalized, has a large commercial market, and is a potential takeover target.